This article is more than 5 years old. Information may no longer be current.

FDA approves generic solution of dorzolamide with timolol

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration approved Lannett Company’s abbreviated new drug application for dorzolamide hydrochloride and timolol maleate ophthalmic solution 2%/0.5%.

The solution is the generic equivalent to Cosopt (Oak Pharmaceuticals).

“The addition of this product exemplifies our team’s capabilities to develop and manufacture medications in a wide variety of forms including solid orals in both immediate and extended release, topicals, oral solutions, parenterals and now ophthalmics,” Arthur P. Bedrosian, CEO of Lannett, said in a press release. “This approval represents our fourth product approved by the FDA thus far in fiscal 2015. We expect to commence shipping the product in the coming months.”